• ქართული
  • English
  • Merck to buy cancer drug developer Peloton for $1.05 billion in cash

    Merck & Co Inc said on Tuesday it would buy Peloton Therapeutics Inc for $1.05 billion in cash to gain access to the privately held company’s renal cancer drug candidate.

    Market Quotes by TradingView